Please Scroll Down to See Forums Below psychedout
New member
I am in a heated arguement at the moment and need all the help I can get.
Any helps is much appreciated.
Any helps is much appreciated.
Ulter, Fonz, Mods/Vets... Need help finiding ephedrine safe studies
- Thread starter psychedout
- Start date
mountain muscle
New member
There is an interesting article on the ephedra ban in Will Brink's column in Musclemag. It doesn't mention any safety studies but compares FDA approved drugs and OTC drugs such as Tylenol and the problems and deaths they have both caused in contrast to ephedra.
Bulldog_10
New member
Used safely to treat incontinence:
Title: Clozapine-induced urinary incontinence: Incidence and treatment with ephedrine.
Author, Editor, Inventor: Fuller-Matthew-A {a}; Brovicka-Mary-C; Jaskiw-George-E; Simon-Michelle-R; Kwon-Kong; Konicki-P-Eric
Author Address: {a} Pharm. Serv. 119(B), 10000 Brecksville Rd., Brecksville, OH 44141, USA
Source: Journal-of-Clinical-Psychiatry. 1996; 57 (11) 514-518.
Publication Year: 1996
Document Type: Research-Article
ISSN (International Standard Serial Number): 0160-6689
Language: English
Abstract: Background: Treatment with the atypical antipsychotic drug clozapine appears to be associated with an increased incidence of urinary incontinence (UI). We posited that the potent anti-alpha-adrenergic effects of clozapine were involved, and hence that an alpha-adrenergic agonist would reduce UI. We tested this hypothesis by using ephedrine, an approved alpha-adrenergic agonist. Method: Fifty-seven inpatients with schizophrenia or schizoaffective disorder (DSM-IV) who met the Kane criteria for being treatment refractory were treated with clozapine (75-900 mg/day). Patients who developed UI were then openly treated with ephedrine in increasing doses until UI was attenuated or a dose of 150 mg/day was attained. Results: Seventeen patients developed UI as evidenced by either urine-stained sheets/clothing or direct patient reports. In 2 cases, the UI was sufficiently severe that adult diapers had to be used. Comparison of patients who developed UI and those who did not showed that UI was associated with female gender and with concomitant treatment with typical antipsychotic drugs. One patient was treated with a behavioral program, but the remaining 16 patients were treated with ephedrine. Ephedrine treatment was very effective, with 15/16 patients showing improvement within 24 hours after reaching maximum ephedrine dosage. Twelve of 16 (including the 2 most severe) eventually had a complete remission of their UI. In the remaining 4 patients, 3 had a reduction in the frequency of UI and 1 showed no response. These benefits have been maintained over the course of 12 months of subsequent treatment for several patients. There were no side effects associated with the use of ephedrine nor were there any changes in neuropsychiatric status. Conclusion: Ephedrine appears to be a safe and effective treatment for clozapine-associated UI. By inference, it is likely that clozapine may cause UI via its anti-alpha-adrenergic properties.
Title: Clozapine-induced urinary incontinence: Incidence and treatment with ephedrine.
Author, Editor, Inventor: Fuller-Matthew-A {a}; Brovicka-Mary-C; Jaskiw-George-E; Simon-Michelle-R; Kwon-Kong; Konicki-P-Eric
Author Address: {a} Pharm. Serv. 119(B), 10000 Brecksville Rd., Brecksville, OH 44141, USA
Source: Journal-of-Clinical-Psychiatry. 1996; 57 (11) 514-518.
Publication Year: 1996
Document Type: Research-Article
ISSN (International Standard Serial Number): 0160-6689
Language: English
Abstract: Background: Treatment with the atypical antipsychotic drug clozapine appears to be associated with an increased incidence of urinary incontinence (UI). We posited that the potent anti-alpha-adrenergic effects of clozapine were involved, and hence that an alpha-adrenergic agonist would reduce UI. We tested this hypothesis by using ephedrine, an approved alpha-adrenergic agonist. Method: Fifty-seven inpatients with schizophrenia or schizoaffective disorder (DSM-IV) who met the Kane criteria for being treatment refractory were treated with clozapine (75-900 mg/day). Patients who developed UI were then openly treated with ephedrine in increasing doses until UI was attenuated or a dose of 150 mg/day was attained. Results: Seventeen patients developed UI as evidenced by either urine-stained sheets/clothing or direct patient reports. In 2 cases, the UI was sufficiently severe that adult diapers had to be used. Comparison of patients who developed UI and those who did not showed that UI was associated with female gender and with concomitant treatment with typical antipsychotic drugs. One patient was treated with a behavioral program, but the remaining 16 patients were treated with ephedrine. Ephedrine treatment was very effective, with 15/16 patients showing improvement within 24 hours after reaching maximum ephedrine dosage. Twelve of 16 (including the 2 most severe) eventually had a complete remission of their UI. In the remaining 4 patients, 3 had a reduction in the frequency of UI and 1 showed no response. These benefits have been maintained over the course of 12 months of subsequent treatment for several patients. There were no side effects associated with the use of ephedrine nor were there any changes in neuropsychiatric status. Conclusion: Ephedrine appears to be a safe and effective treatment for clozapine-associated UI. By inference, it is likely that clozapine may cause UI via its anti-alpha-adrenergic properties.
Bulldog_10
New member
more:
Title: The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans.
Author, Editor, Inventor: Toubro-Soren {a}; Astrup-Arne; Breum-Leif; Quaade-Flemming
Author Address: {a} Research Dep. Human Nutrition, The Royal Veterinary and Agricultural University, 25 Rolighedsvej, DK-1958 Fredriksberg, Copenhagen, Denmark
Source: International-Journal-of-Obesity. 1993; 17 (SUPPL. 3) S73-S77.
Publication Year: 1993
Document Type: Article-
ISSN (International Standard Serial Number): 0307-0565
Language: English
Abstract: This paper describes a 24-week open follow-up trial with reduced obese patients all receiving an ephedrine/ caffeine combination (20 mg/200 mg) three times a day. The study was a continuation of a previous 24-week double-blind placebo-controlled study where the ephedrine/caffeine mixture had shown superior weight-reducing properties when compared with either ephedrine alone (20 mg) or caffeine alone (200 mg) three times a day. The medication was stopped between weeks 24-26 In order to evaluate withdrawal symptoms. The follow-up period was from weeks 26 to 50. Of 127 patients included, 99 completed the follow-up treatment, which resulted in an additional weight loss of 1.1 kg (P = 0.02). Adverse drug reactions were all minor and temporary. We conclude that the ephedrine/caffeine combination is safe and effective in long-term treatment in improving and maintaining weight loss. The side-effects are minor and transient and no clinically relevant withdrawal symptoms have been observed.
Title: The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans.
Author, Editor, Inventor: Toubro-Soren {a}; Astrup-Arne; Breum-Leif; Quaade-Flemming
Author Address: {a} Research Dep. Human Nutrition, The Royal Veterinary and Agricultural University, 25 Rolighedsvej, DK-1958 Fredriksberg, Copenhagen, Denmark
Source: International-Journal-of-Obesity. 1993; 17 (SUPPL. 3) S73-S77.
Publication Year: 1993
Document Type: Article-
ISSN (International Standard Serial Number): 0307-0565
Language: English
Abstract: This paper describes a 24-week open follow-up trial with reduced obese patients all receiving an ephedrine/ caffeine combination (20 mg/200 mg) three times a day. The study was a continuation of a previous 24-week double-blind placebo-controlled study where the ephedrine/caffeine mixture had shown superior weight-reducing properties when compared with either ephedrine alone (20 mg) or caffeine alone (200 mg) three times a day. The medication was stopped between weeks 24-26 In order to evaluate withdrawal symptoms. The follow-up period was from weeks 26 to 50. Of 127 patients included, 99 completed the follow-up treatment, which resulted in an additional weight loss of 1.1 kg (P = 0.02). Adverse drug reactions were all minor and temporary. We conclude that the ephedrine/caffeine combination is safe and effective in long-term treatment in improving and maintaining weight loss. The side-effects are minor and transient and no clinically relevant withdrawal symptoms have been observed.
Bulldog_10
New member
more:
Title: Herbal ephedra/caffeine for weight loss: A 6-month randomized safety and efficacy trial.
Author, Editor, Inventor: Boozer-C-N {a}; Daly-P-A; Homel-P; Solomon-J-L; Blanchard-D; Nasser-J-A; Strauss-R; Meredith-T
Author Address: {a} New York Obesity Research Center, St Luke's-Roosevelt Hospital Center, 1111 Amsterdam Avenue, WH 1029, New York, NY, 10025; E-Mail: [email protected], USA
Source: International-Journal-of-Obesity. [print] May, 2002; 26 (5): 593-604.
Journal URL: http://www.naturesj.com/ijo/index.html
Publication Year: 2002
Document Type: Article-
ISSN (International Standard Serial Number): 0307-0565
Language: English
Abstract: OBJECTIVE: To examine long-term safety and efficacy for weight loss of an herbal Ma Huang and Kola nut supplement (90/192 mg/day ephedrine alkaloids/caffeine). DESIGN: Six-month randomized, double-blind placebo controlled trial. SUBJECTS: A total of 167 subjects (body mass index (BMI) 31.8 +- 4.1 kg/m2) randomized to placebo (n = 84) or herbal treatment (n = 83) at two outpatient weight control research units. MEASUREMENTS: Primary outcome measurements were changes in blood pressure, heart function and body weight. Secondary variables included body composition and metabolic changes. RESULTS: By last observation carried forward analysis, herbal vs placebo treatment decreased body weight (-5.3 +- 5.0 vs -2.6 +- 3.2 kg, P < 0.001), body fat (-4.3 +- 3.3 vs -2.7 +- 2.8 kg, P = 0.020) and LDL-cholesterol (-8 +- 20 vs 0 +- 17 mg/dl, P = 0.013), and increased HDL-cholesterol (+2.7 +- 5.7 vs-0.3 +- 6.7 mg/dl, P = 0.004). Herbal treatment produced small changes in blood pressure variables (+3 to -5 mmHg, P ltoreq 0.05), and increased heart rate (4 +- 9 vs -3 +- 9 bpm, P < 0.001), but cardiac arrhythmias were not increased (P > 0.05). By self-report, dry mouth (P < 0.01), heartburn (P < 0.05), and insomnia (P < 0.01) were increased and diarrhea decreased (P < 0.05). Irritability, nausea, chest pain and palpitations did not differ, nor did numbers of subjects who withdrew. CONCLUSION: In this 6-month placebo-controlled trial, herbal ephedra/caffeine (90/192 mg/day) promoted body weight and body fat reduction and improved blood lipids without significant adverse events.
Title: Herbal ephedra/caffeine for weight loss: A 6-month randomized safety and efficacy trial.
Author, Editor, Inventor: Boozer-C-N {a}; Daly-P-A; Homel-P; Solomon-J-L; Blanchard-D; Nasser-J-A; Strauss-R; Meredith-T
Author Address: {a} New York Obesity Research Center, St Luke's-Roosevelt Hospital Center, 1111 Amsterdam Avenue, WH 1029, New York, NY, 10025; E-Mail: [email protected], USA
Source: International-Journal-of-Obesity. [print] May, 2002; 26 (5): 593-604.
Journal URL: http://www.naturesj.com/ijo/index.html
Publication Year: 2002
Document Type: Article-
ISSN (International Standard Serial Number): 0307-0565
Language: English
Abstract: OBJECTIVE: To examine long-term safety and efficacy for weight loss of an herbal Ma Huang and Kola nut supplement (90/192 mg/day ephedrine alkaloids/caffeine). DESIGN: Six-month randomized, double-blind placebo controlled trial. SUBJECTS: A total of 167 subjects (body mass index (BMI) 31.8 +- 4.1 kg/m2) randomized to placebo (n = 84) or herbal treatment (n = 83) at two outpatient weight control research units. MEASUREMENTS: Primary outcome measurements were changes in blood pressure, heart function and body weight. Secondary variables included body composition and metabolic changes. RESULTS: By last observation carried forward analysis, herbal vs placebo treatment decreased body weight (-5.3 +- 5.0 vs -2.6 +- 3.2 kg, P < 0.001), body fat (-4.3 +- 3.3 vs -2.7 +- 2.8 kg, P = 0.020) and LDL-cholesterol (-8 +- 20 vs 0 +- 17 mg/dl, P = 0.013), and increased HDL-cholesterol (+2.7 +- 5.7 vs-0.3 +- 6.7 mg/dl, P = 0.004). Herbal treatment produced small changes in blood pressure variables (+3 to -5 mmHg, P ltoreq 0.05), and increased heart rate (4 +- 9 vs -3 +- 9 bpm, P < 0.001), but cardiac arrhythmias were not increased (P > 0.05). By self-report, dry mouth (P < 0.01), heartburn (P < 0.05), and insomnia (P < 0.01) were increased and diarrhea decreased (P < 0.05). Irritability, nausea, chest pain and palpitations did not differ, nor did numbers of subjects who withdrew. CONCLUSION: In this 6-month placebo-controlled trial, herbal ephedra/caffeine (90/192 mg/day) promoted body weight and body fat reduction and improved blood lipids without significant adverse events.
Bulldog_10
New member
BTW...this goes against my rule of answering threads where specific people are asked for answers
Bulldog_10
New member
pong21 said:
Mostly iron overdoses I would assume.
Bulldog_10
New member
ulter said:
But don't you think that's kind of skewed due to the fact that probably 75% of people in the US take multi-vitamins everyday?
